Senhwa Biosciences announced it has signed a memorandum of understanding with Global Emerging Markets to secure up to NT$500 million in strategic funding to support its clinical pipeline, AI-driven drug discovery initiatives, and global expansion efforts.
The agreement underscores growing investor interest in AI-enabled biopharma innovation, particularly in areas such as immuno-oncology, where data-driven approaches are increasingly shaping next-generation therapies. The funding is expected to accelerate Senhwa’s research and development programs while strengthening its position in global pharmaceutical markets.
Senhwa has been actively building an AI-powered discovery platform to complement its core focus on cancer immunotherapy. Through collaborations with emerging AI-native companies, the firm is leveraging advanced technologies, including cell-to-sentence modeling, to better understand tumor biology and identify potential combination therapies.
The company’s AI-enabled validation efforts have shown promising immunomodulatory potential for its lead candidates, particularly within specific tumor microenvironments. This supports Senhwa’s “cold-to-hot tumor” strategy, aimed at improving treatment responses by enhancing immune system activity against cancer cells.
The partnership with GEM is expected to provide flexible capital to advance both clinical development and AI integration, while also opening the door to future international collaborations and commercialization opportunities.
